Lead Product(s): TRIObody drug conjugate
Therapeutic Area: Oncology
Highest Development Status: Undisclosed Product Type: Large molecule
Partner/Sponsor/Collaborator: Trio Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 30, 2020
Trio Pharmaceuticals and Ajinomoto Bio-Pharma Services will evaluate AJICAP™, a proprietary site-specific conjugation technology offered by Aji Bio-Pharma for the development of TDCs.